PRIMVAC, developed by Inserm (France), is a is a placental malaria (PM) vaccine candidate derived from VAR2CSA-derived placental malaria (PM) vaccine candidate spanning the CSA-binding DBL1x-2x region of the 3D7-VAR2CSA variant. It is manufactured as a soluble recombinant protein using the E. Coli SHuffle® expression system (Chêne et al., 2018; Chêne et al., 2019). A phase Ia/Ib dosage-escalation clinical trial was conducted in malaria-naïve and exposed nulligravid women to evaluate the safety, reactogenicity, and immunogenicity of PRIMVAC formulated with either Alhydrogel or GLA-SE adjuvants (NCT02658253). No serious adverse events related to the vaccine were reported. PRIMVAC antibody titers increased with each dose, and seroconversion was observed in all vaccinated women (n=57). The highest antibody titers were achieved with a 100 μg dose formulated with GLA-SE, one week after the third vaccination (day 63) (Sirima et al., 2020).